CDK2 and familial pancreatic carcinoma: Importantly, in pancreatic cancer, the anti-tumorigenic activity of IL-33 has been demonstrated through tumor cell-intrinsic downregulation of cellular proliferating proteins, such as CDK2 and CDK4, and upregulation of pro-apoptotic molecules, such as Bax and TRAIL [29].